Strategic paths for biomarker qualification
Open Access
- 20 March 2008
- journal article
- review article
- Published by Elsevier in Toxicology
- Vol. 245 (3), 219-223
- https://doi.org/10.1016/j.tox.2007.12.023
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Implementing the U.S. FDA guidance on pharmacogenomic data submissionsEnvironmental and Molecular Mutagenesis, 2007
- Biomarker qualification pilot process at the US Food and Drug AdministrationThe AAPS Journal, 2007
- The Experience with Voluntary Genomic Data Submissions at the FDA and a Vision for the Future of the Voluntary Data Submission ProgramClinical Pharmacology & Therapeutics, 2007
- Biomarkers and Surrogate End Points for Fit-for-Purpose Development and Regulatory Evaluation of New DrugsClinical Pharmacology & Therapeutics, 2007
- Process map proposal for the validation of genomic biomarkersPharmacogenomics, 2006
- Fit-for-Purpose Method Development and Validation for Successful Biomarker MeasurementPharmaceutical Research, 2006
- The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM): A Review of the ICCVAM Test Method Evaluation Process and Current International Collaborations with the European Centre for the Validation of Alternative Methods (ECVAM)Alternatives to Laboratory Animals, 2002
- Use of Biomarkers and Surrogate Endpoints in Drug Development and Regulatory Decision Making: Criteria, Validation, StrategiesAnnual Review of Pharmacology and Toxicology, 2001